Human Vaccines Market Share

Name: Human Vaccines Market Research Report - Forecast to 2035
Creator: Market Research Future
License: https://www.marketresearchfuture.com/pages/terms-and-conditions

ID: MRFR/Pharma/1984-HCR

200 Pages

Rahul Gotadki

October 2025

Human Vaccines Market Research Report By Vaccine Type (Inactivated, Live Attenuated, Subunit, Recombinant, Toxoid), By Application (Preventive Vaccines, Therapeutic Vaccines, Travel Vaccines, Influenza Vaccines), By Administration Route (Intramuscular, Subcutaneous, Oral, Intradermal), By Target Diseases (Infectious Diseases, Oncological Diseases, Autoimmune Diseases) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa)-Forecast to 2035

Request Free Sample

Summary Table of Contents Segmentation Download PDF

Market Share

Human Vaccines Market Share Analysis

Companies operating in the competitive climate of human vaccines market position themselves strategically by diversifying their vaccine-based portfolio to cover a wide range of diseases. Through the production of vaccines that target several infectious illnesses, businesses increase their market portfolios and meet changing healthcare demands. This approach not only creates a broad product range but also brands companies as leaders in the fight against several preventable diseases. Companies strive to increase market share by exploring the emerging markets and enhancing vaccine availability. Strategic initiatives are therefore undertaken to ensure that underserved populations in developing regions benefit from global vaccination delivery. In this way, companies help address the public health problems and improve their market share because they meet unmet needs in different demographics while broadening the markets. Companies assess their positioning in the ever-changing atmosphere of vaccine development through investments into some groundbreaking technologies. This includes innovations in vaccine platforms like mRNA, vector-basin as well recombinant technologies. Through leading the way in technology innovation, companies distinguish themselves from their rivals and gain first-mover advantage with regard to prevailing market positioning for being a developer of innovative and performing vaccine solutions. How the market share is positioned in the human vaccines sector greatly depends on strategic collaborations and alliances. Collaboration between pharmaceutical firms, research institutions and international organizations leads to sharing of specialization, resources and speeding up vaccine production. By ensuring such collaborations, the capabilities of companies are advanced; their reach is boosted and they become crucial stakeholders in global mass immunization drives. Safety and efficacy issues form the basis of market share positioning strategy. Companies make investments in intense research and clinical trials to validate the efficacy and safety profiles of their vaccines. The emphasis on transparency and compliance with regulatory standards creates trust among healthcare professionals and the population, which results in an increase of market acceptance as well favourable positioning. Early market penetration in high demand markets is a strategic act to gain enough shares of the market. Competitive advantage is enjoyed by companies that react in anticipation to identify an upcoming health threat or market need and swiftly launch vaccines. This early entry does not only address urgent healthcare needs fast but also creates a first-mover advantage in markets where there is high demand for countermeasures. Flexibility in manufacturing processes and a robust supply chain are key for market share positioning in the human vaccines market.

Market Highlights

Author

Rahul Gotadki

Assistant Manager

He holds an experience of about 7+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. In addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives

Get In Touch

FAQs

What is the projected growth of the Middle East-Africa Human Vaccines market?

The Middle East-Africa Human Vaccines market is the expected increase in total market value of 1.23 USD billion over a defined forecast period 2025–2035. It is driven by factors such as demand trends, technological advances, regulatory changes, and geographic expansion.

What is the size of the Middle East-Africa Human Vaccines market?

Middle East-Africa Human Vaccines market size was valued at approximately 0.67 billion USD in 2024. This figure will reach 1.23 billion USD covering all regions (America, Europe, Asia, MEA and ROW), focusing its segments / services / distribution channels till 2035.

What is the CAGR of the Middle East-Africa Human Vaccines market?

Middle East-Africa Human Vaccines market is expected to grow at a CAGR of 5.72% between 2025 and 2035.

How much will the Middle East-Africa Human Vaccines market be worth by 2035?

Middle East-Africa Human Vaccines market is expected to be worth of 1.23 billion USD, reflecting growth driven by usage, technology and global demands by the end of 2035.

How will the Middle East-Africa Human Vaccines market perform over the next 10 years?

Over the next 10 years the Middle East-Africa Human Vaccines market is expected to shift from usd billion 0.67 to 1.23 billion USD, led by adoption of advanced tech, demographic trends, regulatory approvals, with potential headwinds from 2025 to 2035.

Which region is projected to hold the largest market share in the Global Human Vaccines Market by 2035?

North America is projected to hold the largest market share, valued at 32.0 USD Billion by 2035.

What will be the market size of Inactivated vaccines in the Global Human Vaccines Market by 2035?

The market size for Inactivated vaccines is expected to reach 23.0 USD Billion by 2035.

Who are the major players in the Global Human Vaccines Market?

Major players in the Global Human Vaccines Market include Pfizer, Merck and Co, AbbVie, and Roche among others.

What is the expected market value for the Live Attenuated vaccine segment by 2035?

The Live Attenuated vaccine segment is expected to reach a market value of 15.5 USD Billion by 2035.

How much is the market for Subunit vaccines expected to grow by 2035?

The market for Subunit vaccines is projected to grow to 12.0 USD Billion by 2035.

1. Market Overview

2. Market Trends

3. Market Segment Insights

4. Key Players and Competitive Insights

5. Industry Developments

6. Market Segmentation

7. Report Scope

8. Market Highlights

9. FAQs

Customize Report

Certified Researchers

Market Summary

As per Market Research Future Analysis, the Human Vaccines Market is projected to grow significantly, driven by the increasing prevalence of infectious diseases and heightened public awareness of vaccination benefits. The market is expected to expand from 50.22 USD Billion in 2025 to 1.23 USD Billion by 2035, reflecting a CAGR of 4.14% during the forecast period. Key drivers include substantial investments in research and development, public-private partnerships, and advancements in vaccine technology, such as mRNA and personalized vaccines.

Key Market Trends & Highlights

The Global Human Vaccines Market is witnessing transformative trends that are shaping its future.

Market Size in 2024: 0.67 USD Billion; Expected to reach 1.23 USD Billion by 2035. Inactivated vaccines valued at 15.0 USD Billion in 2024, projected to grow to 23.0 USD Billion by 2035. Public awareness campaigns have increased immunization coverage for DTP vaccines to over 85% globally. North America leads the market with a valuation of 20.0 USD Billion in 2024, expected to grow to 32.0 USD Billion by 2035.

Market Size & Forecast

2024 Market Size	USD 0.67 Billion
2035 Market Size	USD 1.23 Billion
CAGR (2025-2035)	5.72%
Largest Regional Market Share in 2024	North America.

Major Players

Key Companies include <a href="https://www.pfizer.com/science/vaccines/research">Pfizer</a>, Merck and Co, AbbVie, Roche, Gilead Sciences, Johnson and Johnson, Bristol Myers Squibb, Novartis, <a href="https://investor.regeneron.com/news-releases/news-release-details/regeneron-joins-human-vaccines-project-improve-global-disease">Regeneron Pharmaceuticals</a>, Bayer, Moderna, AstraZeneca, GlaxoSmithKline, Sanofi.

Market Trends

The Global Human Vaccines Market is witnessing significant trends driven by various market factors. A key market driver is the increasing prevalence of infectious diseases and the need for preventative healthcare measures. With growing awareness of vaccination benefits, governments and healthcare organizations are investing in vaccination programs to prevent outbreaks and enhance public health.

This heightened focus on preventive healthcare is leading nations to support initiatives aimed at increasing vaccination coverage and developing innovative vaccines. Opportunities to be explored in this market include advancements in vaccine technology, such as mRNA technology and personalized vaccines.

As researchers continue to innovate, there is potential for the introduction of new and effective vaccine formulations that cater to specific populations and evolving pathogens. Furthermore, as global travel increases and disease patterns change, there is an increasing demand for vaccines that address emerging infectious diseases, presenting a chance for companies to develop specialized products.

In recent times, trends show a significant increase in public-private partnerships to facilitate vaccine research and distribution, as seen during the COVID-19 pandemic. This collaboration has not only expedited vaccine development timelines but has also highlighted the importance of global cooperation in addressing health crises.

Furthermore, the push towards universal vaccination programs to ensure equitable access across diverse populations has gained momentum, reflecting a commitment to global health security. Overall, these trends underscore a dynamic environment where innovation, collaboration, and public health priorities shape the future of the Global Human Vaccines Market.

Human Vaccines Market Market Drivers

Increasing Global Vaccination Coverage

The Global Human Vaccines Market Industry is experiencing growth due to the increasing emphasis on vaccination coverage across various populations. Governments worldwide are implementing policies aimed at enhancing immunization rates, particularly in developing regions. For instance, initiatives by the World Health Organization focus on achieving universal vaccination coverage, which is projected to significantly impact market dynamics. As of 2024, the market is valued at approximately 48.2 USD Billion, reflecting the importance of vaccination in public health strategies. This trend is expected to continue, with a projected market value of 78.5 USD Billion by 2035, indicating a sustained commitment to improving global health outcomes.

Market Segment Insights

Human Vaccines Market Vaccine Type Insights

The Global Human Vaccines Market is poised for considerable growth, with a notable focus on the Vaccine Type segment, which includes various classifications like Inactivated, Live Attenuated, Subunit, Recombinant, and Toxoid vaccines. The overall market is expected to witness a substantial rise, with projections indicating a value of 50.22 USD Billion in 2024 and reaching 78.5 USD Billion by 2035. Within this landscape, the Inactivated segment holds the majority, valued at 15.0 USD Billion in 2024 and projected to grow to 23.0 USD Billion by 2035.

This segment is vital due to its effectiveness in immunizing against a range of diseases without causing the infection itself, making it a safe choice for broad population use. Following closely is the Live Attenuated segment, expected to be valued at 10.0 USD Billion in 2024 and rise to 15.5 USD Billion by 2035. Live Attenuated vaccines are significant as they offer robust immunity and often require fewer doses, thereby ensuring better compliance among different demographics.

The Subunit vaccines are valued at 8.0 USD Billion in 2024, increasing to 12.0 USD Billion by 2035, which makes them critical due to their ability to use only specific parts of the virus or bacteria, reducing side effects while maintaining efficacy.

Human Vaccines Market Application Insights

This segment encompasses critical applications including Preventive Vaccines, Therapeutic Vaccines, Travel Vaccines, and Influenza Vaccines. Preventive Vaccines are crucial in preventing infectious diseases, thus significantly impacting global health outcomes. Furthermore, Therapeutic Vaccines are gaining traction in treating chronic diseases and cancers, leading to innovations in Research and Development.

Travel Vaccines cater to health-conscious travelers, promoting safety and disease prevention across borders, while Influenza Vaccines remain essential given the seasonal outbreaks, ensuring community health is prioritized. With such diverse applications, the Global Human Vaccines Market revenue is set to expand, backed by rising public health initiatives and awareness around vaccine benefits, despite challenges such as logistics and public skepticism. Understanding this landscape through Global Human Vaccines Market segmentation is vital for stakeholders to harness opportunities and enhance vaccine accessibility.

Human Vaccines Market Administration Route Insights

The Administration Route plays a crucial role in this market, as it encompasses various methods used to deliver vaccines effectively. This segmentation includes routes such as Intramuscular, Subcutaneous, Oral, and Intradermal administration, each of which presents unique advantages. Intramuscular administration is particularly notable for its rapid immune response, making it a preferred choice for many vaccines, including those targeting diseases like influenza and COVID-19

.Subcutaneous routes are gaining traction due to their ease of administration, especially for patients who require self-administration. Oral vaccination presents an innovative approach that can improve accessibility and adherence, while Intradermal administration is being explored for its potential to reduce vaccine dosages and improve immunogenicity. As the Global Human Vaccines Market data shows, the increasing focus on vaccination programs worldwide, along with advances in vaccine delivery technologies, is a driving force behind the growth and significance of these administration routes.

The ongoing challenges of vaccine hesitancy and logistical issues create pathways for innovative solutions in this sector. The Global Human Vaccines Market statistics suggest that the various administration methods are integral to achieving widespread vaccine coverage and combating infectious diseases on a global scale.

Human Vaccines Market Target Diseases Insights

The landscape is primarily shaped by various diseases, including Infectious Diseases, Oncological Diseases, and Autoimmune Diseases. <a href="https://www.marketresearchfuture.com/reports/infectious-disease-drug-market-43143">Infectious Disease vaccines</a> remain crucial due to their role in preventing outbreaks and protecting public health, while Oncological Diseases vaccines are gaining importance in cancer prevention and treatment, reflecting advancements in Research and Development.

Autoimmune Diseases, often complex and diverse, present significant challenges for vaccine development yet represent a growing area of interest for addressing chronic health issues. The increasing prevalence of these diseases, coupled with technological advancements and a growing understanding of the immune system, contributes to the market growth. With a compound annual growth rate of 4.14 expected for the period from 2025 to 2035, the sector is well-positioned to adapt to emerging health challenges while continuously making strides in vaccine effectiveness and safety.

The Global Human Vaccines Market statistics indicate a trend toward personalized and targeted therapies, emphasizing the importance of addressing diverse health needs on a global scale.

Get more detailed insights about Human Vaccines Market Research Report - Forecast to 2035

Regional Insights

The Global Human Vaccines Market is characterized by diverse regional dynamics shaping its growth trajectory. In 2024, North America leads with a valuation of 20.0 USD Billion, expected to grow to 32.0 USD Billion by 2035, reflecting significant investments in Research and Development and robust healthcare infrastructure. Europe follows with a market value of 12.5 USD Billion in 2024, projected to rise to 20.0 USD Billion, highlighting the region's focus on innovation and advanced immunization strategies.

The Asia-Pacific (APAC) region is projected to reach 10.0 USD Billion in 2024, with growth anticipated to 15.0 USD Billion, driven by a rapidly expanding population and increasing healthcare accessibility.South America is valued at 4.0 USD Billion in 2024, growing to 6.0 USD Billion, showcasing improvements in vaccination coverage amidst economic advancements. The Middle East and Africa (MEA) hold a current market value of 3.72 USD Billion, progressing to 5.5 USD Billion, as investments in healthcare infrastructure rise, enhancing vaccine delivery systems.

The dominance of North America, in particular, underscores the significant role of regulatory frameworks and funding in vaccine development, while the growth in APAC indicates a burgeoning demand for vaccines amid increasing healthcare expenditure.

Human Vaccines Market Segment

Source: Primary Research, Secondary Research, Market Research Future Database and Analyst Review

Key Players and Competitive Insights

The Global Human Vaccines Market is characterized by robust competition and constant innovation, driven by the critical importance of vaccines in preventing diseases and safeguarding public health. As the market expands, various pharmaceutical companies vie for leadership, investing heavily in research and development to create more effective vaccine solutions.

Factors such as increasing prevalence of infectious diseases, emerging global health threats, and the rising demand for vaccines worldwide are shaping the competitive landscape. As a result, companies are not only focusing on advanced research but also forming strategic alliances and partnerships, which enhance their capabilities in delivering innovative vaccine options to meet global health needs.

Pfizer has established itself as a formidable player in the Global Human Vaccines Market, underpinned by its extensive portfolio and deep-rooted commitment to vaccine development. The company’s strengths lie in its advanced technological platforms and strong RD capabilities, which allow it to deliver a wide range of vaccines targeting various infectious diseases.

Pfizer’s global presence is reinforced through its strategic partnerships, collaborations with healthcare organizations, and robust distribution networks, enabling it to reach diverse markets effectively. The company's significant investment in innovative vaccine research has resulted in breakthroughs that have addressed urgent global health concerns, further solidifying its position in the competitive landscape.

Merck and Co a significant footprint in the Global Human Vaccines Market, focusing on the development of innovative vaccines and therapeutic solutions for infectious diseases. Renowned for its key products, Merck offers vaccines that target diseases such as HPV, measles, and influenza. The company has been proactive in expanding its market presence through strategic mergers and acquisitions, allowing it to integrate novel technologies and enhance its research capabilities.

Merck’s strong emphasis on vaccine development is reflected in its commitment to global health initiatives aimed at increasing accessibility and expanding immunization programs. Its well-established reputation for high-quality products and strong pipeline of vaccine candidates positions Merck as a leader in the market committed to advancing public health through continuous innovation and responsive product offerings.

Key Companies in the Human Vaccines Market market include

Industry Developments

Recent developments in the Global Human Vaccines Market have been significantly influenced by various factors, including the ongoing response to infectious diseases and advancements in vaccine technology. In October 2023, Pfizer announced a collaboration with Moderna to enhance mRNA vaccine production efficiency, reflecting an industry trend toward partnerships for rapid vaccine development. Meanwhile, Merck and Co confirmed their investment in next-generation vaccine platforms to combat emerging pathogens, showcasing a commitment to innovation in vaccine efficacy and safety.

Currently, companies like Gilead Sciences and Johnson and Johnson are focusing on expanding their pipeline, especially in therapeutic vaccines targeting HIV and cancer, while Roche and Novartis are investing in biopharmaceuticals to enhance immunogenicity. Notably, GlaxoSmithKline has reported a substantial increase in vaccine sales, attributing this to rising vaccination rates globally.

In the past two to three years, the market has seen significant growth due to increased vaccination campaigns, particularly against COVID-19, with AstraZeneca and Sanofi making strides in vaccine distribution. The combined efforts of these leading firms illustrate a dynamic landscape in the Global Human Vaccines Market, emphasizing innovation and strategic collaborations to address public health challenges.

Future Outlook

Human Vaccines Market Future Outlook

The Human Vaccines Market is projected to grow at a 4.14% CAGR from 2025 to 2035, driven by technological advancements, increasing vaccination awareness, and expanding global health initiatives.

New opportunities lie in:

Invest in mRNA vaccine technology for rapid response to emerging pathogens. Develop combination vaccines to enhance immunization coverage and patient compliance. Leverage digital health platforms for vaccine tracking and patient engagement.

By 2035, the Human Vaccines Market is expected to be robust, reflecting substantial advancements and increased global health commitments.

Market Segmentation

Outlook

North America
Europe
South America
Asia Pacific
Middle East and Africa

Human Vaccines Market Application Outlook

Preventive Vaccines
Therapeutic Vaccines
Travel Vaccines
Influenza Vaccines

Human Vaccines Market Vaccine Type Outlook

Inactivated
Live Attenuated
Subunit
Recombinant
Toxoid

Human Vaccines Market Target Diseases Outlook

Infectious Diseases
Oncological Diseases
Autoimmune Diseases

Human Vaccines Market Administration Route Outlook

Intramuscular
Subcutaneous
Oral
Intradermal

Report Scope

Report Attribute/Metric	Details
Market Size 2024	0.22 (USD Billion)
Market Size 2025	0.67 (USD Billion)
Market Size 2035	1.23 (USD Billion)
Compound Annual Growth Rate (CAGR)	5.72% (2025 - 2035)
Report Coverage	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
Base Year	2024
Market Forecast Period	2025 - 2035
Historical Data	2019 - 2024
Market Forecast Units	USD Billion
Key Companies Profiled	Pfizer, Merck and Co, AbbVie, Roche, Gilead Sciences, Johnson and Johnson, Bristol Myers Squibb, Novartis, Regeneron Pharmaceuticals, Bayer, Moderna, AstraZeneca, GlaxoSmithKline, Sanofi
Segments Covered	Vaccine Type, Application, Administration Route, Target Diseases, Regional
Key Market Opportunities	Rising infectious disease outbreaks, Increasing vaccination awareness, Expansion of vaccine pipelines, Growth in healthcare funding, Advancements in vaccine technology
Key Market Dynamics	Increasing vaccine demand, Technological advancements, Government support and funding, Global health initiatives, Rising infectious diseases.
Countries Covered	North America, Europe, APAC, South America, MEA